News

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 30 July 2026.

The board of Mankind Pharma at its meeting held on 11 July 2026, has inter-alia, considered and approved the: proposal for divestment of 100% stake held in Broadway Hospitality Services (Broadway), a wholly owned subsidiary company; and incorporation of a wholly owned subsidiary company in Netherlands (WOS) to act as a Special Purpose Vehicle for holding investments in R&D assets and business development activities focused on treatment of niche therapies.

Mankind Pharma announced that the 35th Annual General Meeting(AGM) of the company will be held on 4 August 2026.

Mankind Pharma has allotted 80,872 equity shares under ESOP on 19 May 2026. Consequently, the paid up equity share capital has increased to 41,29,09,200 equity shares having face value of Re 1/- each.

Net profit of Mankind Pharma rose 31.75% to Rs 554.35 crore in the quarter ended March 2026 as against Rs 420.77 crore during the previous quarter ended March 2025. Sales rose 11.81% to Rs 3442.93 crore in the quarter ended March 2026 as against Rs 3079.37 crore during the previous quarter ended March 2025.For the full year,net profit declined 3.92% to Rs 1912.93 crore in the year ended March 2026 as against Rs 1990.96 crore during the previous year ended March 2025. Sales rose 16.96% to Rs 14277.64 crore in the year ended March 2026 as against Rs 12207.44 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3442.933079.37 12 14277.6412207.44 17 OPM %27.0122.19 -25.3424.72 - PBDT905.41746.30 21 3348.613137.55 7 PBT682.33515.43 32 2462.432516.33 -2 NP554.35420.77 32 1912.931990.96 -4 Powered by Capital Market - Live News